Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| ciliated cell | 8 studies | 31% ± 11% | |
| epithelial cell of proximal tubule | 7 studies | 37% ± 8% | |
| epithelial cell | 7 studies | 40% ± 16% | |
| hematopoietic precursor cell | 4 studies | 22% ± 4% | |
| natural killer cell | 4 studies | 17% ± 2% | |
| basal cell | 4 studies | 31% ± 16% | |
| conventional dendritic cell | 3 studies | 31% ± 14% | |
| B cell | 3 studies | 17% ± 1% | |
| fibroblast | 3 studies | 27% ± 6% | |
| abnormal cell | 3 studies | 26% ± 13% | |
| macrophage | 3 studies | 22% ± 4% | |
| GABAergic neuron | 3 studies | 20% ± 2% | |
| glutamatergic neuron | 3 studies | 31% ± 5% | |
| dendritic cell | 3 studies | 37% ± 3% | |
| intestinal crypt stem cell | 3 studies | 20% ± 3% | |
| hepatocyte | 3 studies | 36% ± 22% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| bladder | 100% | 2112.19 | 21 / 21 | 100% | 21.22 | 504 / 504 |
| esophagus | 100% | 2256.36 | 1445 / 1445 | 100% | 14.98 | 183 / 183 |
| liver | 100% | 5390.64 | 226 / 226 | 100% | 22.49 | 406 / 406 |
| ovary | 100% | 1906.41 | 180 / 180 | 100% | 15.49 | 430 / 430 |
| prostate | 100% | 2324.82 | 245 / 245 | 100% | 18.18 | 502 / 502 |
| uterus | 100% | 2029.08 | 170 / 170 | 100% | 20.57 | 459 / 459 |
| breast | 100% | 3286.44 | 459 / 459 | 100% | 22.99 | 1117 / 1118 |
| thymus | 100% | 3150.49 | 653 / 653 | 100% | 14.40 | 604 / 605 |
| intestine | 100% | 1939.55 | 966 / 966 | 100% | 16.83 | 525 / 527 |
| lung | 100% | 1809.99 | 576 / 578 | 100% | 18.46 | 1154 / 1155 |
| skin | 100% | 2665.49 | 1809 / 1809 | 99% | 17.91 | 469 / 472 |
| stomach | 100% | 1759.87 | 359 / 359 | 99% | 15.62 | 284 / 286 |
| kidney | 100% | 4304.46 | 89 / 89 | 99% | 35.38 | 894 / 901 |
| pancreas | 99% | 1333.21 | 326 / 328 | 99% | 13.35 | 177 / 178 |
| brain | 98% | 1475.30 | 2594 / 2642 | 100% | 11.64 | 704 / 705 |
| adrenal gland | 100% | 2210.81 | 258 / 258 | 96% | 8.45 | 221 / 230 |
| adipose | 100% | 2799.94 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 21.96 | 29 / 29 |
| muscle | 100% | 2467.69 | 803 / 803 | 0% | 0 | 0 / 0 |
| spleen | 100% | 1507.06 | 241 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 100% | 20.28 | 45 / 45 |
| ureter | 0% | 0 | 0 / 0 | 100% | 5.79 | 1 / 1 |
| blood vessel | 100% | 2135.72 | 1334 / 1335 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 98% | 12.86 | 78 / 80 |
| heart | 97% | 1568.63 | 833 / 861 | 0% | 0 | 0 / 0 |
| peripheral blood | 55% | 1138.90 | 514 / 929 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0006541 | Biological process | glutamine metabolic process |
| GO_0006528 | Biological process | asparagine metabolic process |
| GO_0006107 | Biological process | oxaloacetate metabolic process |
| GO_0005813 | Cellular component | centrosome |
| GO_1904724 | Cellular component | tertiary granule lumen |
| GO_0070062 | Cellular component | extracellular exosome |
| GO_0005829 | Cellular component | cytosol |
| GO_0005576 | Cellular component | extracellular region |
| GO_0035580 | Cellular component | specific granule lumen |
| GO_0106008 | Molecular function | 2-oxoglutaramate amidase activity |
| GO_0050152 | Molecular function | omega-amidase activity |
| Gene name | NIT2 |
| Protein name | Omega-amidase NIT2 (EC 3.5.1.3) (Nitrilase homolog 2) Nitrilase family member 2 |
| Synonyms | CUA002 |
| Description | FUNCTION: Has omega-amidase activity . The role of omega-amidase is to remove potentially toxic intermediates by converting 2-oxoglutaramate and 2-oxosuccinamate to biologically useful 2-oxoglutarate and oxaloacetate, respectively . . |
| Accessions | F8WF58 H7C579 ENST00000460317.1 ENST00000497785.1 ENST00000394140.9 Q9NQR4 ENST00000480073.5 F8WF70 |